Atara Biotherapeutics Announces Executive and Director Changes
Ticker: ATRA · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
Related Tickers: ATRA
TL;DR
Atara Biotherapeutics shuffled execs and board members on Sept 2nd. Watch for strategy shifts.
AI Summary
Atara Biotherapeutics, Inc. announced on September 2, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers.
Why It Matters
Changes in leadership and board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, warranting closer monitoring.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- September 02, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1280 Rancho Conejo Blvd (address) — Principal Executive Offices
- Thousand Oaks, California (location) — Principal Executive Offices
- 91320 (zip_code) — Principal Executive Offices
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What specific roles were affected by the executive and director changes?
The filing indicates the departure of certain officers and directors, the election of new directors, and changes to compensatory arrangements for certain officers, but does not specify the exact roles affected in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 02, 2025.
What is the principal executive office address for Atara Biotherapeutics, Inc.?
The principal executive offices are located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the filing date of this 8-K report?
The report was filed as of September 04, 2025.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-09-03 18:05:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- atra-20250902.htm (8-K) — 40KB
- 0000950170-25-112898.txt ( ) — 139KB
- atra-20250902.xsd (EX-101.SCH) — 23KB
- atra-20250902_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: September 3, 2025 By: /s/ Yanina Grant-Huerta Yanina Grant-Huerta Chief Accounting Officer